エルトロンボパグ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "エルトロンボパグ" in Japanese language version.

refsWebsite

Global rank Japanese rank

9nih.gov

4^th place

24^th place

7doi.org

2^nd place

6^th place

3glaxosmithkline.co.jp

low place

2gsk.com

low place

5,782^nd place

2hematologylibrary.org

low place

1pmda.go.jp

6,690^th place

394^th place

1novartis.co.jp

low place

9,532^nd place

1worldcat.org

5^th place

19^th place

doi.org

Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE (Mar 2014). “Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug”. Blood 123 (12): 1818–25. doi:10.1182/blood-2013-10-534743. PMID 24345753.
Townsley, Danielle M.; Scheinberg, Phillip; Winkler, Thomas; Desmond, Ronan; Dumitriu, Bogdan; Rios, Olga; Weinstein, Barbara; Valdez, Janet et al. (2017-04-20). “Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia”. New England Journal of Medicine 376 (16): 1540–1550. doi:10.1056/NEJMoa1613878. ISSN 0028-4793. PMC 5548296. PMID 28423296.
Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL (Jun 2007). “Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist”. Blood 109 (11): 4739–41. doi:10.1182/blood-2006-11-057968. PMID 17327409.
Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM (Nov 2007). “Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura”. The New England Journal of Medicine 357 (22): 2237–2247. doi:10.1056/NEJMoa073275. PMID 18046028.
McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH (Nov 2007). “Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C”. The New England Journal of Medicine 357 (22): 2227–2236. doi:10.1056/NEJMoa073255. PMID 18046027.
Garnock-Jones KP, Keam SJ (2009). “Eltrombopag”. Drugs 69 (5): 567–76. doi:10.2165/00003495-200969050-00005. PMID 19368418.
Roth, M.; Will, B.; Simkin, G.; Narayanagari, S.; Barreyro, L.; Bartholdy, B.; Tamari, R.; Mitsiades, C. S. et al. (2012). “Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation”. Blood 120 (2): 386–394. doi:10.1182/blood-2011-12-399667. PMC 3398759. PMID 22627766.

glaxosmithkline.co.jp

“Revolade（一般名：エルトロンボパグ）、欧州で慢性特発性血小板減少性紫斑病の適応で承認される”. グラクソ・スミスクライン (2010年3月23日). 2015年8月27日閲覧。
“慢性特発性血小板減少性紫斑病治療薬「レボレード」承認取得”. グラクソ・スミスクライン (2010年10月27日). 2015年8月27日閲覧。
“グラクソ・スミスクラインのPromacta（一般名：エルトロンボパグ）免疫抑制療法（IST）に抵抗性の重症再生不良性貧血（SAA）患者に対する新たな適応症でFDAから承認を取得”. グラクソ・スミスクライン (2014年9月17日). 2015年9月17日閲覧。

gsk.com

“GSK gains FDA Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for severe aplastic anaemia”. GSK Press Release. GSK. 28 March 2014閲覧。
"FDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder" (Press release). グラクソ・スミスクライン. 20 November 2008. 2008年11月25日閲覧。

hematologylibrary.org

bloodjournal.hematologylibrary.org

Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE (Mar 2014). “Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug”. Blood 123 (12): 1818–25. doi:10.1182/blood-2013-10-534743. PMID 24345753.
Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL (Jun 2007). “Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist”. Blood 109 (11): 4739–41. doi:10.1182/blood-2006-11-057968. PMID 17327409.

nih.gov

pubmed.ncbi.nlm.nih.gov

Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE (Mar 2014). “Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug”. Blood 123 (12): 1818–25. doi:10.1182/blood-2013-10-534743. PMID 24345753.
Townsley, Danielle M.; Scheinberg, Phillip; Winkler, Thomas; Desmond, Ronan; Dumitriu, Bogdan; Rios, Olga; Weinstein, Barbara; Valdez, Janet et al. (2017-04-20). “Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia”. New England Journal of Medicine 376 (16): 1540–1550. doi:10.1056/NEJMoa1613878. ISSN 0028-4793. PMC 5548296. PMID 28423296.
Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL (Jun 2007). “Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist”. Blood 109 (11): 4739–41. doi:10.1182/blood-2006-11-057968. PMID 17327409.
Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM (Nov 2007). “Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura”. The New England Journal of Medicine 357 (22): 2237–2247. doi:10.1056/NEJMoa073275. PMID 18046028.
McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH (Nov 2007). “Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C”. The New England Journal of Medicine 357 (22): 2227–2236. doi:10.1056/NEJMoa073255. PMID 18046027.
Garnock-Jones KP, Keam SJ (2009). “Eltrombopag”. Drugs 69 (5): 567–76. doi:10.2165/00003495-200969050-00005. PMID 19368418.
Roth, M.; Will, B.; Simkin, G.; Narayanagari, S.; Barreyro, L.; Bartholdy, B.; Tamari, R.; Mitsiades, C. S. et al. (2012). “Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation”. Blood 120 (2): 386–394. doi:10.1182/blood-2011-12-399667. PMC 3398759. PMID 22627766.

ncbi.nlm.nih.gov

Townsley, Danielle M.; Scheinberg, Phillip; Winkler, Thomas; Desmond, Ronan; Dumitriu, Bogdan; Rios, Olga; Weinstein, Barbara; Valdez, Janet et al. (2017-04-20). “Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia”. New England Journal of Medicine 376 (16): 1540–1550. doi:10.1056/NEJMoa1613878. ISSN 0028-4793. PMC 5548296. PMID 28423296.
Roth, M.; Will, B.; Simkin, G.; Narayanagari, S.; Barreyro, L.; Bartholdy, B.; Tamari, R.; Mitsiades, C. S. et al. (2012). “Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation”. Blood 120 (2): 386–394. doi:10.1182/blood-2011-12-399667. PMC 3398759. PMID 22627766.

novartis.co.jp

“ノバルティスの「レボレード」、このクラスで初の重症再生不良性貧血の治療薬として、EUから承認を取得”. ノバルティス (2015年9月16日). 2015年9月17日閲覧。

pmda.go.jp

info.pmda.go.jp

“レボレード錠12.5mg／レボレード錠25mg 添付文書” (2016年9月). 2016年11月4日閲覧。

worldcat.org

search.worldcat.org

Townsley, Danielle M.; Scheinberg, Phillip; Winkler, Thomas; Desmond, Ronan; Dumitriu, Bogdan; Rios, Olga; Weinstein, Barbara; Valdez, Janet et al. (2017-04-20). “Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia”. New England Journal of Medicine 376 (16): 1540–1550. doi:10.1056/NEJMoa1613878. ISSN 0028-4793. PMC 5548296. PMID 28423296.